Tag: information

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.

Virtual Events Include Investor Webinar and Presentation at Emerging Growth Conference 85

MARKHAM, Ontario, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of August 2025, representing $0.936 per Common Share on an annualized basis.

BOCA RATON, FL, Aug. 15, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it now holds approximately 1,420,173 SOL and SOL equivalents on its balance sheet, inclusive of rewards generated through staking and onchain activities. The increase follows the Company’s acquisition of 110,000 SOL at an average price of $201.68, representing a total value of approximately $22 million.

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) --  Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 42,300 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on August 12, 2025 (the “Grant Date”), in connection with the commencement of employment.

CHICAGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- LanzaTech Global, Inc. (“LanzaTech” or the “Company”) (NASDAQ: LNZA), a leading carbon capture and transformation company, today announced that it will implement a 1-for-100 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock (the “Common Stock”), effective August 18, 2025 at 5:00 p.m. Eastern Time. Immediately prior to effecting the Reverse Stock Split, LanzaTech will decrease the par value of the Common Stock from $0.0001 to $0.0000001 per share (the “Par Value Change”) and increase the number of authorized shares of Common Stock from 600,000,000 to 2,580,000,000 (the “Authorized Share Increase”). At the effective time of the Reverse Stock Split, the number of authorized shares of Common Stock will be proportionately decreased to 25,800,000. The Reverse Stock Split, Par Value Change, and Authorized Share Increase were approved by stockholders at LanzaTech's 2025 Annual Meeting of Stockholders held on July 28, 2025.

Not for distribution to U.S. newswire services or dissemination in the United States.